Viral Vectors in Cancer Immunotherapy, Volume 379 (Hardcover)

Viral Vectors in Cancer Immunotherapy, Volume 379 in the International Review of Cell and Molecular Biology presents the latest on cancer immunotherapy and how it has transformed cancer treatment through advances in immune checkpoint inhibitors and adoptive cell therapy. Chapters in this new release include Past, present and future of viral vectors in cancer immunotherapy, Alphaviruses in cancer immunotherapy, Adenoviral-based cancer gene therapy, Armored modified vaccinia Ankara in cancer immunotherapy, Strategies of Semliki Forest virus in immuno-oncology, Maraba virus in cancer immunotherapy, Oncolytic viruses in hematological malignancies, Oncolytic virus for cancer therapies: Overview and future directions, and more. The use of genetically modified viruses allows the expression of pro-inflammatory molecules, while the immune system receives danger signals from the viruses themselves. In some cases, the virus can also induce tumor cell death. This book will review advances in virus-based cancer immunotherapy in both solid tumors and hematologic malignancies.

General

Imprint:	Academic Press Inc
Country of origin:	United States
Series:	International Review of Cell and Molecular Biology
Release date:	August 2023
First published:	2023
Volume editors:	Fernando Aranda Vega • Pedro Berraondo • Lorenzo Galluzzi
Dimensions:	229 x 151mm (L x W)
Format:	Hardcover
Pages:	277
ISBN-13:	978-0-443-19249-4
Categories:	Books > Science & Mathematics > Biology, life sciences > Developmental biology Books > Science & Mathematics > Biology, life sciences > Molecular biology Books > Science & Mathematics > Biology, life sciences > Cellular biology > General Promotions
LSN:	0-443-19249-9
Barcode:	9780443192494

Is the information for this product incomplete, wrong or inappropriate? Let us know about it.

Does this product have an incorrect or missing image? Send us a new image.

Is this product missing categories? Add more categories.

Review This Product

No reviews yet - be the first to create one!